Method for Inhibiting Platelet Interaction with Biomaterial Surfaces

• US 20090023004A1
• Filed: 09/26/2008
• Published: 01/22/2009
• Est. Priority Date: 03/28/2007
• Status: Abandoned Application

• Current Assignee: Medtronic ATS Medical, Inc. (Medtronic Plc)
• Original Assignee: Medtronic ATS Medical, Inc. (Medtronic Plc)
• Inventors: Pederson, Brian
• Application Number:
  US12/238,958
• Publication Number:
  US 20090023004A1
• Time in Patent Office: Days
• US Class Current: 428/478.200
• CPC Class Codes: A61L 2300/42 Anti-thrombotic agents, anticoagulants, anti-platelet agents
• CPC Class Codes: A61L 33/0041 characterised by the choice of an antithrombatic agent other than heparin heparinoïd A61L33/08; polypeptides A61L33/12
• CPC Class Codes: A61L 33/0094 Physical treatment, e.g. plasma treatment
• CPC Class Codes: A61L 33/062 Mixtures of macromolecular compounds
• CPC Class Codes: A61L 33/126 Fibrin
• CPC Class Codes: A61L 33/128 Other specific proteins or polypeptides not covered by A61L33/122 - A61L33/126
• CPC Class Codes: A61N 1/05 for implantation or insertion into the body, e.g. heart electrode A61N1/06 takes precedence
• CPC Class Codes: A61N 1/375 Constructional arrangements, e.g. casings
• CPC Class Codes: A61N 1/37512 Pacemakers
• CPC Class Codes: Y10T 428/31768 Natural source-type polyamide [e.g., casein, gelatin, etc.]

Abstract

A method for passivating a biomaterial surface includes modifying proteinaceous material disposed at the biomaterial surface. The passivation may be effectuated by exposing the biomaterial surface to therapeutic electrical energy in the presence of blood or plasma.

Claims

1. A method for passivating a biomaterial surface, said method comprising obtaining a qualitatively modified fibrinogen at said biomaterial surface.

2. A method as in claim 1 wherein said qualitatively modified fibrinogen includes an increased level of β

-chain fibrinogen.

3. A method as in claim 1 wherein said qualitatively modified fibrinogen includes a decreased level of α

-chain and γ

-chain fibrinogen.

4. A method as in claim 1 wherein said biomaterial surface is a portion of a medical article.

5. A passivated biomaterial surface including a qualitatively modified fibrinogen.

6. A passivated biomaterial surface as in claim 5 wherein said biomaterial surface has an electrical resistivity of less than about 5 ohms.

7. A passivated biomaterial surface as in claim 6 wherein said biomaterial surface is selected from pyrolytic carbon, titanium, nitinol, stainless steel, platinum, or iridium.